|

Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease

RECRUITINGN/ASponsored by Singapore General Hospital
Actively Recruiting
PhaseN/A
SponsorSingapore General Hospital
Started2025-11-01
Est. completion2028-07
Eligibility
Age21 Years – 70 Years
Healthy vol.Accepted

Summary

This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves liver health and metabolic function. The study consists of two components. The first is a cross-sectional case-control study comparing urinary acylglycine concentrations and other glycine-dependent metabolic parameters between 60 participants with MASLD and 30 healthy controls. The second is a randomized, double-blind, placebo-controlled trial in which 60 participants with MASLD will receive either oral glycine supplementation (9 g/day) or placebo for 26 weeks. The primary outcomes are differences in urinary acylglycine concentrations between participants with MASLD and healthy controls, and changes in hepatic fat content measured by MRI-PDFF and urinary acylglycine concentrations following supplementation. Additional assessments will evaluate amino acid metabolism, glutathione metabolism, oxidative stress, inflammatory responses, and one-carbon metabolism-related biomarkers. Participants will undergo baseline, Week 12, and Week 26 assessments to evaluate metabolic changes and treatment responses.

Eligibility

Age: 21 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

All subjects:

1. Age 21-70 years
2. Ability to provide informed consent.

MASLD group:

1. Hepatic steatosis on MRI
2. BMI of 25-50 kg/m2

Controls:

1. Absence of hepatic steatosis on MRI
2. BMI of 18.5-24.9 kg/m2
3. No chronic disease
4. No long-term medications

Exclusion Criteria:

1. Uncontrolled diabetes (HbA1c \> 8%)
2. Type 1 Diabetes Mellitus
3. Clinically significant anemia (Haemoglobin \< 10 g/dL)
4. Chronic liver disorders (except MASLD) such as Hepatitis B, Hepatitis C, Wilson's disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic disorders, and liver cirrhosis
5. Drugs that may induce hepatic steatosis, such as methotrexate, amiodarone, tamoxifen, or Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)
6. Glomerular filtration rate (GFR \< 30 ml/min)
7. Serum alanine transaminase (ALT) \> 3x upper limit of normal (ULN)
8. Serum aspartate transaminase (AST) \> 3x ULN
9. Liver cirrhosis
10. Significant alcohol consumption (\> 20g/day for women and \>30g/day for men)
11. Pregnancy
12. Uncontrolled thyroid disease
13. Previous bariatric surgery
14. Weight loss \> 5% in the past 1 month
15. Metallic implants (including incompatible pacemakers, AICD, metallic heart valves) or other contraindications to MRI
16. Claustrophobia
17. Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other, or family members)

Conditions2

Liver DiseaseMetabolic Dysfunction-associated Fatty Liver Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.